Lanadelumab in Long-term Prophylaxis of Acquired Angioedema
Status: Recruiting
Location: See location...
Intervention Type: Biological
Study Type: Interventional
Study Phase: Phase 4
SUMMARY
use of lanadelumab in patients with acquired angioedema
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• A diagnosis of AAE with recurrent attacks without urticaria (decreased C1INH functional, quantitative levels, decreased C4 and decreased C1q levels, no family history of angioedema), presence of anti-C1INH antibody and/or paraproteinemia (e.g. monoclonal gammopathy of unknown significance)
• historical attack rate of \>= on attack per month prior to starting tranexamic acid (TAA)
Locations
United States
Ohio
Bernstein Clinical Research Center, LLC
RECRUITING
Cincinnati
Contact Information
Primary
Karen Berendts
kberendts@bernsteincrc.com
513-354-1746
Backup
Jonathan Bernstein, MD
bernstja@ucmail.uc.edu
Time Frame
Start Date: 2024-06-01
Estimated Completion Date: 2027-12-01
Participants
Target number of participants: 5
Treatments
Other: open-label administration
all subjects receive open-label lanadelumab
Related Therapeutic Areas
Sponsors
Leads: Bernstein Clinical Research Center